BioSpace News Archive

Chemotherapy has considerably transformed the paradigm of cancer treatment and management all over the world.

Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, reported business highlights and financial results for the first quarter ended March 31, 2021.

Itamar Medical Ltd., a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced its WatchPAT® technology was highlighted in a panel discussion on sleep apnea during Ladenburg Thalmann’s Healthcare Symposia Series.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced the development program expansion of vidutolimod into non-melanoma skin cancers in combination with Libtayo® under a clinical supply agreement with Regeneron Pharmaceuticals, Inc.

Reimagined virtual experience will be broadcast nationwide for the first time on YES TV to unite Canadians as a force-for-life in the face cancer

Initiated darovasertib plus crizotinib combination Phase 1/2 dose expansion based on early clinical activity observed in first cohort; additional dose exploration ongoing

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that Mike Burgess, M.B.Ch.B., Ph.D. has been appointed Head of Research and Development.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2021.

The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release syndrome.

Eagle expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) and Rapid Infusion (“RI”) formulations